CB1 receptor (CB1R) antagonists have been demonstrated to be effective in treating obesity and related disorders. This study has been focused on establishing a β-arrestin 2-based screening assay for the CB1R using BRET 2 technology. When the existing BRET 2 screening platform was applied to the CB1R, the authors discovered that the receptor interacted weakly with β-arrestin 2, resulting in unsatisfactory assay performance. To enhance the β-arrestin binding capacity, they replaced the C-terminal tail of the CB1R with tails from either the V2 or BRS3 receptors, both of which interact strongly with β-arrestin 2. Using this chimeric approach, the authors screened a small compound library and identified 21 antagonist and inverse agonist hits with IC 50 and EC 50 values ranging from 0.3 nM to 7.5 µM. Both primary and secondary screening were performed with Z′ > 0.5, suggesting that the assay is a robust and cost-effective alternative to existing cell-based assays. (Journal of Biomolecular Screening 2009:371-380) 
INTRODUCTION
C ontemporary human behavior related to feeding and physical activity is associated with a dramatic increase in the incidence of obesity in virtually all modern societies. Among the targets explored in recent years, the endocannabinoid system is proving to be one of the most promising and intriguing ones. 1, 2 The endocannabinoid system includes 2 major receptors, the cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R), and their corresponding endogenous lipidlike ligands. 3, 4 The CB1R, a 7-transmembrane (7TM) receptor, and its ligands, the endocannabinoids, play an important role in the regulation of appetite behavior and overall energy metabolism. This receptor is among the most abundant 7TM receptors expressed in the brain but is also expressed in peripheral organs, including the gastrointestinal tract, adipose tissue, liver, pancreas, heart, and vascular tissue. 5, 6 Pharmacologic blockade or genetic ablation of CB1Rs causes a transient reduction in food intake accompanied by sustained weight loss. 6, 7 It is believed that most major pharmaceutical companies are undertaking parallel CB1R antagonist development programs. 8 The first marketable CB1R antagonist/inverse agonist, rimonabant (Acomplia; Sanofi-Aventis, Bridgewater, NJ), is associated with major CNS (depression, anxiety, dizziness) and gastrointestinal (nausea, diarrhea) side effects. Similar concerns have been raised about other centrally acting CB1R blockers in development, thus shifting the interest toward the development of peripherally acting CB1R ligands. 1, 2 However, CB1R evaluation as a drug target has been hindered due to the hydrophobic nature of its lipid-based ligands, low expression level of recombinant CB1R cDNA in cellular cultures, and low amplification in the signaling cascade. 3, 9 The CB1R couples primarily to Gα i/o to inhibit cAMP production; decrease and increase Ca 2+ and K + conductance, respectively; and increase mitogen-activated protein kinase activity. 3 The functional cell based [ 35 S]-GTPγ-S binding assay is traditionally used for 7TM receptors coupled to the Gα i/o proteins (reviewed in Milligan 10 and Harrison and Traynor 11 ). This radioactivity-based assay is both expensive and requires increasingly comprehensive permissions. 12 Recently, fluorescence and bioluminescence resonance energy transfer (FRET and BRET, respectively) assays have been developed, which measure physical interactions between 2 proteins fused to a donor and acceptor moiety, respectively. The signal is dependent on their intermolecular distance (10-100 Å) and on relative orientation. 13 In BRET 2 -based assays, Renilla luciferase (Rluc) is used as donor and the green fluorescent protein (GFP) variant GFP 2 as the acceptor molecule. This BRET pair results in a broad Stokes shift of 115 nm, enabling well-defined separation of the Rluc and GFP light and therefore higher sensitivity than classic BRET. We have previously described an optimized BRET 2 arrestin/receptor screening assay using β-arrestin 2 (β-arr2) mutants for increased performance. 14 In view of the described role of β-arr2 in the desensitization of the CB1 receptor 15 and reported interaction between the arrestin 2 (β-arr1) and a fragment of the CB1R C-terminal tail, 16 we tested the applicability of our established screening platform 14 for the CB1R. We found that the receptor performed poorly in this assay compared to numerous other receptors tested. Several reports reveal that stable receptor/β-arrs complexes can be achieved either by mutations in β-arrs 14, 17 or by switching the receptor C-terminal tails [18] [19] [20] as we have previously demonstrated. [21] [22] [23] In this study, we report development of a BRET 2based screening assay specifically tailored for the CB1R and its applicability in full-plate primary and secondary screening. 
MATERIALS AND METHODS

Materials
Green fluorescent protein (GFP 2 ) and Renilla luciferase (Rluc) fusion constructs
Human β-arr2 N-terminally tagged with GFP 2 (GFP 2 /β-arr2), GFP 2 -Rluc, and vasopressin receptor type 2-Rluc fusion vector (V2R-RLuc) were purchased from PerkinElmer BioSignal, Inc. (Montreal, Canada). Mutation Arg 393,395 →Glu introduced in human GFP 2 /β-arr2 (GFP 2 /β-arr2 R393E,R395E) using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) was previously described and characterized. 14 The commercial use of the GFP 2 /β-arr2 R393E,R395E mutant requires a license from 7TM Pharma. The C-terminally Rluctagged CB1R (CB1R-RLuc) and bombesin receptor subtype 3 (BRS3/Rluc) were made using standard molecular biology techniques. To create the CB1 chimeric receptors (CB1R-V2R tail and CB1R-BRS3 tail chimera), we swapped the CB1R C-terminal tail (T418-Stop473) with that of the V2R (G345-Stop372) and BRS3 (E351-Stop400). Rluc fusion constructs of both chimeric receptors were also prepared (CB1R-V2R tail/ Rluc and CB1R-BRS3 tail/Rluc). All generated cDNA clones are in the expression vector pcDNA3.1(+) and were verified by sequencing.
Cell culture and transfection
HEK-293 cells were routinely maintained and passaged in minimum essential medium (MEM) supplemented with 10% (v/v) heat-inactivated fetal calf serum (HIFCS), 2 mM Glutamax-I, 1% NEAA, 1% NaPyr, penicillin (100 U/mL), and streptomycin (100 µg/mL). The HEK-293 cells were incubated at 37 °C in a humidified atmosphere of 5% (v/v) CO 2 in air. HEK-293 cells were stably transfected with GFP 2 /β-arr2 R393E,R395E using Lipofectamine, thus creating a clonal cell line designated as HEK-385. For transient transfection, HEK-293 and HEK-385 cells were seeded at density 4 × 10 6 cells per 75-cm 2 flask, and transfections were performed the following day using Lipofectamine.
Inositol phosphate assay
An inositol phosphate (IP) assay based on the principles of immobilized metal ion affinity chromatography and SPA 24 was used to determine agonist-induced IP accumulation in HEK-293 cells expressing the BRS3 and CB1R constructs. To enable the Gα i/o -selective CB1R and chimeras thereof to activate the phospholipase Cβ (PLC-β) pathway, we used a previously characterized promiscuous Gα q66Di5 mutant. 25 A receptor/Gα q66Di5 ratio of 3:1 was used for the respective cDNAs. One day after transfection, the cells were transferred to poly-D-lysine-treated 96-well culture plates at a density of 30,000 cells/well and were incubated for 24 h with 1 µCi of [ 3 H]-myoinositol in 0.1 mL of growth medium per well. Cells were then washed twice in Hanks' balanced salt solution (HBSS). Subsequently, cells were stimulated in 0.1 mL of the same buffer supplemented with 10 mM LiCl at 37 °C for 45 min with the appropriate agonist ligands (BRS3 Analog 1 or CP 55,940; 10 -12 to 10 -6 M final concentration). Cells were extracted by addition of 50 µL of 10 mM formic acid to each well followed by incubation on ice for 30 min. The amount of [ 3 H]-inositol phosphates generated in the cells was determined by measurement of the radioactivity on YSi SPA beads with a TopCount microplate reader (Packard BioScience, Montreal, Canada). Determinations were made in triplicate. The obtained data were transferred to GraphPad Prism and EC 50 values (nM ± SEM) generated by using sigmoidal dose-response curve fitting.
cAMP assay
The cAMP AlphaScreen assay (PerkinElmer, Waltham, MA) was used to determine cAMP accumulation in living cells according to the manufacturer's instruction (for details, see www.perkinelmer.com) and as described previously. 26 Briefly, 48 h after transfection of HEK-293 cells with the V2R constructs, 20 µL cells (~20,000 cells) resuspended in stimulation buffer (0.1× HBSS, 5 mM HEPES, 0.5 mM IBMX, 0.1% bovine serum albumin [BSA]; pH 7.4) was distributed to wells in 384-well microplates (white Optiplate; Packard BioScience). Cells were then stimulated for 60 min at room temperature with increasing concentration of [8-arginine]-vasopressin ([Arg8]-VP; 10 -14 to 10 -7 M final concentration). Cells were then incubated for 10 min with the anti-cAMP-conjugated acceptor beads before biotinylated cAMP/streptavidin-coated donor beads conjugate was added. Both acceptor beads and biotinylated cAMP/donor bead conjugate were prepared in lysis buffer (5 mM HEPES, 0.3% Tween-20, 0.1% BSA, 10 mM MgCl 2 ). The plates were read after a 1-, 6-, and 12-h incubation at room temperature using a Fusion (PerkinElmer). The interaction between donor and acceptor beads was detected by measuring the emission of acceptor beads (520-620 nm) after excitation of donor beads at 680 nm; agonist-induced cAMP production is therefore read as a signal reduction. The percentage of initial signal reduction was calculated using the following equation: % inhibition = [(S -S 0 )/(S MAX -S 0 )*100], where S is the signal, and S MAX is the maximal AlphaScreen signal measured in the absence of agonist. The AlphaScreen signal not displaced by the highest agonist concentration was regarded as a background (S 0 ). Determinations were made in 8 replicates. Obtained data were transferred to GraphPad Prism and EC 50 values (nM ± SEM) generated using sigmoidal doseresponse curve fit.
BRET 2 agonist assay
BRET 2 measurements with the Mithras LB 940 plate reader equipped with 4 injectors (Berthold Technologies, Bad Wildbad, Germany) were performed as previously described. 12, 14 Briefly, following harvesting, 180 µL resuspended cells containing ~200,000 cells was distributed to wells in 96-well microplates (white Optiplate; Packard BioScience) in the presence of increasing concentrations (10 -12 to 10 -6 M, final concentration) of the V2R agonist [Arg8]-VP, BRS3 agonist BRS3 Analog 1, or CB1R agonist CP 55,940 and incubated for 5 min. The substrate Coelenterazine 400a was diluted to 100 µM in a special assay solution that ensures prolonged stability (30% EtOH/70% Dulbecco's phosphate-buffered saline [D-PBS] supplemented with glucose and pyruvate) and was then added by injector 1 to a final concentration of 5 µM. Readings were collected 2 s after injections. The signals detected at 395 nm and 515 nm were measured sequentially and the 515/395 ratios calculated and expressed as a miliBRET level (mBU; BRET ratio × 1000).
BRET 2 antagonist primary screening
A library of 260 selected compounds synthesized at 7TM Pharma or acquired from commercial libraries was tested. The library and reference compounds (i.e., the CB1R agonist CP 55,940 and the CB1R antagonist rimonabant) were prepared as 10 mM stock solutions in DMSO. Due to the hydrophobic nature of CB1R ligands, it was necessary to dissolve the compounds in DMSO, and therefore the previously developed protocol for BRET 2 -based agonist and antagonist screening 14 was not suitable for performing the CB1R-BRS3 tail antagonist screening. As the minimal amount of ligands injected by the Mithras injector is 10 µL, the concentration of DMSO would be too high. Therefore, we introduced some modifications to the established protocol. First, 1 µL of the test compound (1 µM final concentration) and 1 µL of CB1R agonist CP 55,940 (50 nM final concentration), both dissolved in DMSO, were transferred into wells in 96-well microplates (white Optiplate; Packard BioScience) using a Biomek FX (Beckman Coulter, Fullerton, CA). Negative and positive controls were in columns 1 (wells 1-8) and 12 (wells 89-96). Two wells in each column contained 1 µM CP 55,940, 3 wells contained 50 nM CP 55,940 (EC 80 concentration), and 3 wells contained DMSO (1 vol %); the 2 latter groups of values were used for Z′ calculations. Subsequently, plates were transferred to the Mithras LB 940 reader, where injector 1 injected 2 times successively 90 µL of resuspended cells to each well in the entire plate (plate mode). A 5-min delay was then introduced before 10 µL of the substrate Coelenterazine 400a (final concentration 5 µM) was injected to each well by injector 2 and readings collected 2 s after injections. With this modified protocol, the final vol % of DMSO was kept at an acceptable level (below 2 vol %), and cells in all wells were subjected to a 10-min concomitant incubation with the test compound and reference agonist before BRET 2 measurements. Obtained data were analyzed by MDL  Assay Explorer  (Symyx Technologies, Inc., San Ramon, CA) and Z′ values calculated. The antagonist screening with the selected library was repeated 3 times.
BRET 2 antagonist secondary and inverse agonism screening
Secondary antagonist screening (antagonist dose-response curves) was performed in a similar way as the primary screening (see above). First, 1 µL of increasing concentrations ranging from 10 -10 to 5 × 10 -5 M (final concentration) of the test compound and 1 µL of CB1R agonist CP 55,940 (50 nM final concentration), both dissolved in DMSO, were transferred into wells in 96-well microplates (white Optiplate; Packard BioScience) using a Biomek FX. Negative and positive controls were in columns 1 and 12. Two wells in each column contained 1 µM CP 55,940, 3 wells contained 50 nM CP 55,940 (EC 80 concentration), and 3 wells contained DMSO (1 vol %). To obtain inverse agonist dose-response curves, we transferred 1 µL of increasing concentrations of the test compounds ranging from 10 -10 to 5 × screening, 2 rimonabant dose-response curves (10 -10 to 10 -6 M) were prepared in row 1. The rest of the protocol was the same as described above for primary screening.
Luminescence and fluorescence measurements
Expression levels of Rluc-and GFP 2 -tagged constructs for each BRET 2 experiment were monitored by luminescence and fluorescence measurements as described previously. 14
RESULTS
Agonist-induced BRET 2 signal
In an attempt to establish a β-arrestin-based BRET 2 screening assay for the CB1R, we initially tested whether the agonist-stimulated interaction between β-arr2 and the wildtype (WT) CB1R results in appropriate BRET 2 signals. As depicted in Figure 1 , the CB1R agonist-induced increase in the BRET 2 signal was minimal (<10 mBU) compared to other 7TM receptors, exemplified here by the V2R and BRS3. This was also the case when our previously described β-arr2 R393E,R395E mutant 14 was used. Maximal agonist-induced BRET 2 signal (BRET max ) obtained for the BRS3/β-arr2 interaction was almost 10-fold higher than the BRET max obtained for the V2R (see Fig. 1 ). The inability of the β-arr2 mutant to improve the BRET 2 signal led us to employ a receptor chimeric approach that was proven successful with some other 7TM receptors. [18] [19] [20] [21] [22] [23] We created CB1R chimeric constructs where the C-terminal tail of the CB1R was replaced with that of the V2R (G345-Stop372) or the BRS3 (E351-Stop400; see Fig. 2 ).
Tails were exchanged after the putative amphipathic helix 8 of the CB1R in position T418 to ensure functionality. 27 The generated receptor chimeric constructs showed activity comparable to nonchimeric constructs (see Table 1 ). Receptor interactions with both WT and mutant β-arr2 were investigated in the BRET 2 assay (Fig. 3A) . The observed BRET 2 signal for the CB1R was greatly improved with the replacement of its C-terminal tail with that of the V2R or BRS3. It was also observed that coexpression with the β-arr2 mutant considerably improved the BRET 2 signal in the case of the CB1R-BRS3 tail construct (see Fig. 3A ). On the basis of these data, we decided to continue our work using a HEK-293 cell line stably expressing the GFP 2 /β-arr2 R393E,R395E mutant, designated as the HEK-385 cell line (Fig. 3B) , thus improving the robustness of the assay, as previously also shown by Bertrand et al. 28 The obtained BRET 2 data for the CB1R tail-swapped constructs in the HEK-385 cells are comparable to those observed in transiently transfected HEK-293 cells. Again, the CB1R-BRS3 tail chimera performed better than the CB1R-V2R tail chimera (see Fig. 3A, B) . The applicability of the tail swap strategy was also tested with another receptor that was nonresponding in the classical BRET 2 assay, the melanocortin-4 (MC4) receptor. The addition of the BRS3 tail to the MC4 receptor resulted in a robust BRET 2 assay (7TM Pharma; unpublished).
Constitutive BRET 2 signal
The described receptor constructs also exhibited variable constitutive interaction (BRET const ) with both β-arr2 and the β-arr2 R393E,395E mutant in the absence of agonist. The BRS3 and CB1R-BRS3 tail-swapped chimera exhibited the highest BRET const with the β-arr2 R393E,R395E mutant (≈40-80 mBU). The CB1R-V2R tail-swapped constructs exhibited moderate constitutive interaction with both WT and mutant β-arr2 (around 30 mBU), whereas BRET const for the CB1 and V2 receptors was only between 10 and 15 mBU (data not shown). secondary screening (≈30 vs. ≈100 mBU), but that was anticipated from the obtained BRET const signal in HEK-293 cells. IC 50 and EC 50 values were then calculated from the BRET 2 antagonist and inverse agonism dose-response curves, respectively, and Table 2 provides assay results for a selected subset of the most active compounds. The entire list of 21 compounds can be found in Supplementary Table 1 (http://jbx.sagepub.com/supplemental). The tested hits displayed higher potency when tested in inverse agonism mode than in antagonist mode; however, the rank order of potency remained comparable. The rank order of potencies obtained in BRET 2 assays also correlates well with that obtained in the classical [ 35 S]-GTPγ-S assay (7TM Pharmaunpublished; see Table 2 and Supplementary Table 1 ).
DISCUSSION
Faced by challenges of identifying new lead compounds (potential drug candidates) and reducing the cost, the demand for novel technologies and approaches for improving the efficiency of existing screening platforms has intensified in recent years. In the present study, we combined 2 different approaches (mutation in β-arr2 and C-terminal tail swapping) to enhance the CB1R binding to β-arr2 and developed a robust and costeffective BRET 2 -based screening platform with acceptable Z′ values (>0.5). Initially, it was observed that the agonist-induced interaction between β-arr2 and the CB1R resulted in an almost negligible BRET 2 signal. Only a slight increase was observed when our previously described β-arr2 mutant 14 was used. This was intriguing as it was anticipated that the CB1R/β-arr2 mutant interaction would result in a substantially increased BRET 2 signal. This result suggests that mutations in β-arr2 alone are not always sufficient to enhance receptor-arrestin interaction.
Screening assays
As the BRET 2 signal obtained for the CB1R-BRS3 tailswapped construct resulted in robust agonist dose-response curves with pharmacology similar to that found in other assays, we also tested the applicability of the generated CB1R-BRS3 tail chimera in a BRET 2 -based antagonist screening assay. A library of 260 compounds was first screened in single concentration (1 µM; Fig. 4 ; for details see Materials and Methods). We screened 4 consecutive 96-well plates in antagonist mode on 3 separate occasions, and Z′ values for the plates ranged from 0.63 to 0.83. Twenty-one compounds inhibited the agonistinduced signal (50 nM CP 55,940; EC 80 concentration) more than 50% and were defined as hits and selected for further characterization. Subsequently, secondary antagonist screening (antagonist dose-response curves) was performed on 3 consecutive 96-well plates. Figure 5 shows the BRET 2 antagonist dose-response curves generated in the presence of 50 nM CB1R agonist CP 55,940 (EC 80 ) and increasing concentration of either hits identified in primary antagonist screening or the known CB1R antagonists rimonabant (Fig. 5, plates 1-A, 2-A,  and 3-A) . Z′ values for the secondary antagonist screening ranged from 0.76 to 0.88. As the CB1R-BRS3 tail chimera also displayed constitutive interaction with the β-arr2 R395E,R395E mutant, we next investigated the possibility of detecting inverse agonism with this newly established BRET 2 assay (Fig. 5, plates  1-B, 2-B, and 3-B) . Here, cells were treated only with an increasing concentration of identified hits or rimonabant, and the decrease in BRET 2 signal relative to untreated cells was measured. The assay performed poorer compared to the primary and secondary antagonist screening, although the Z′ values were still satisfactory (>0.5) and ranged from 0.53 to 0.58. The assay window was also smaller in inverse agonism screening compared to primary and Previous studies have revealed that distinct domains within the C-terminal tail mediate CB1R internalization and desensitization. 15, 29 Residues between 460 and 463 are required for its internalization, 29 whereas residues between 418 and 439 are important for β-arr2-mediated desensitization. 15 A synthetic diphosphorylated peptide corresponding to the same region of the CB1R (residues 419-438) that is involved in desensitization also bound β-arr1. 16 Based on the reported CB1R/β-arr1 binding, it could be assumed that the CB1R belongs to class B 7TM receptors. 18 Serine/threonine clusters that mediate the formation of stable receptor/β-arr complexes in this class of receptors are present within the CB1R C-terminal tail, but based on the previous findings, 17,30 their position is not appropriate to support this role. This is not the case with the contextual position of these clusters in the V2 19 and BRS3 receptors. The obvious question was whether the affinity of the CB1R/β-arr2 interaction can be enhanced to a degree that a BRET 2 -based screening assay would become feasible. This led us to generate chimeric receptors of the CB1R with tails of either the V2 or BRS3 receptor (CB1R-V2R tail and CB1R-BRS3 tail). The V2R C-terminal tail was selected because its role in mediating the formation of stable receptor/β-arr complexes is well established. 17, 19 In addition, the V2R has also been successfully used in the β-arrestin-based BRET 2 assay 28 as well as in the Transfluor  arrestin recruitment assay. 31 The C-terminal tail of the BRS3 receptor was included here, as it is the most potent receptor tested so far in our running BRET 2 screening assays (7TM Pharma; unpublished), even though studies regarding the BRS3 modulatory process (internalization, desensitization, downregulation) are lacking (for review, see Jensen et al. 32 ). Tails were exchanged after the amphipatic helix 8 of the CB1R at position Thr418, as a junction between transmembrane domain 7 and helix 8 occurs at the Arg401. 33 Helix 8 is required for proper CB1R-G-protein interaction, 27 whereas the distal C-terminal tail domain (amino acids 418-472) was reported only to modulate magnitude and kinetics of signaling. 34 Therefore, domains important for CB1R ligand binding and G-protein interactions were preserved in the generated CB1R chimeras. However, one should be aware that the chimeric receptor could exhibit properties different from the WT receptor.
The agonist-induced CB1R interaction with β-arr2 resulted in a substantially increased BRET 2 signal after introduction of V2R or BRS3 tails, where the CB1R-BRS3 chimera performed better than the CB1R-V2R chimera. The CB1R-BRS3 construct interacted more efficiently with the β-arr2 mutant than with WT β-arr2. Because mutation R393E destabilizes the polar core, 35 it is possible that phosphorylation is a limiting step for the CB1R-BRS3/β-arr2 interaction. BRET max obtained in transiently transfected HEK-293 cells and the HEK-385 stable cell line was comparable or moderately improved in HEK-385 for certain receptor/β-arr2 pairs. This could be due to a more optimal receptor/arrestin ratio in the stable cell line; to obtain an optimal BRET 2 signal, the GFP 2 -arrestin level should preferably exceed the receptor expression. 36 Modifications of the existing protocol 14 were also necessary to run the assay in fully automated mode due to the hydrophobic nature of the CB1R ligands and technical limitations connected with the existing instrumentation (i.e., minimal volume injected by injectors). We demonstrated that pretreatment with antagonist/test compound is not necessary to run primary or secondary antagonist screening, but the cells can be incubated concomitantly with agonist and antagonist/test compounds. The modified CB1R BRET 2 screening assay has the ability to identify known CB1R ligands (rimonabant and CP55,940) in addition to 21 hits that were found to specifically inhibit agonist-induced β-arr2 recruitment to the CB1R; 2 of them displayed higher potency than rimonabant. The CB1R-BRS3 construct also displayed a substantial constitutive interaction (BRET const ) with β-arr2 constructs. This correlates well with both constitutive endocytosis 37 as well as constitutive activity (reviewed in Howlett et al. 3 and Mukhopadhyay et al. 27 ) displayed by the CB1R. Some of the known CB1R antagonists (SR141716A [rimonabant], AM251, AM281, Ly320135) also behaved as inverse agonists. 38 Therefore, we also tested the applicability of the established BRET 2 assay for inverse agonist screening. We found the established inverse agonism assay performed acceptably and that Z′ values were satisfactory, and thereby this assay allows rapid discrimination between neutral antagonists and inverse agonists. This could be of particular interest because inverse agonists may have different therapeutic properties compared to neutral antagonists. 39 Other existing cell-based assays used for screening the CB1R are GTPγ-S binding and IP assays using promiscuous Gα proteins. 40 However, the agonist-induced assay window is relatively small in both assays due to the constitutive activity of the CB1R and relatively low amplification in the signaling cascade (e.g., in striatum, each CB1R activates only 3 G-proteins; reviewed in Howlett et al. 3 ). Taken together, this is the first study to our knowledge that describes a BRET 2 -based screening assay specifically customized for the CB1R, and its successful application in medium-throughput screening/high-throughout screening could provide highly qualified leads for the treatment FIG. 5 . BRET 2 -based secondary antagonist and inverse agonist dose-response curves for selected hits. (A) Secondary antagonist screening (antagonist dose-response curves) was performed for 21 compounds identified in primary antagonist screening. First, 1 µL of increasing concentrations of the test compound ranging from 10 -10 to 5 × 10 -5 M (final concentration) and 1 µL of CB1R agonist CP 55,940 (50 nM final concentration), both dissolved in DMSO, were transferred into wells of 96-well microplates (white Optiplate) using a Biomek FX. Negative and positive controls were in columns 1 (wells 1-8) and 12 (wells 89-96). Two wells in each column contained 1 µM CP 55,940, 3 wells contained 50 nM CP 55,940 (EC 80 concentration), and 3 wells contained DMSO (1 vol %). Furthermore, a rimonabant dose-response curve (each concentration in duplicate; 10 -10 to 10 -6 M) was prepared in row 1. (B) The selected compounds were also tested in inverse agonism mode. First, 1 µL of increasing concentrations of the test compounds ranging from 10 -10 to 5 × 10 -5 M (final concentration) dissolved in DMSO was transferred into wells of 96-well microplates (white Optiplate) using a Biomek FX. Negative (1 vol % DMSO) and positive (1 µM rimonabant) controls were in columns 1 (wells 1-8) and 12 (wells 89-96). Furthermore, a rimonabant dose-response curve (each concentration in duplicate; 10 -10 to 10 -6 M) was prepared in row 1. Subsequently, plates were transferred to the Mithras LB 940 reader, where 180 µL of resuspended cells containing ~200,000 cells was distributed in 96-well microplates by the Mithras injector 1. Substrate Coelenterazine 400a (final concentration 5 µM) was then injected by injector 2 and BRET 2 signals measured as described under Materials and Methods. Data shown are mean ± SEM of duplicate observations from a single representative screening experiment. of a number of conditions via CB1R pharmacotherapy. Most likely, the tail swap strategy could also be applied to other weak arrestin-binding receptor targets (e.g., the MC4 receptor).
